BackgroundFinerenone and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM), while the relative efficacy has not been determined.MethodsThe databases of PubMed, Embase and Cochrane were searched for relevant cardiovascular or renal outcome trials of SGLT2i or finerenone. The end points were major adverse cardiovascular events (MACE), nonfatal stroke (NS), myocardial infarction (MI), hospitalization for heart failure (HHF), cardiovascular death (CVD), and renal composite outcome (RCO). Network meta-analysis was performed using Bayesian networks to obtain pooled hazard ratios (HR) and 95% confidence intervals (CI). The probability val...
Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patien...
Aim: To evaluate the effect of finerenone by baseline HbA1c, HbA1c variability, diabetes duration an...
Background: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on heart failure (HF) o...
BackgroundThe nonsteroidal mineralocorticoid antagonist finerenone is a new addition to the list of ...
Cardiovascular and renal impairment are the most common complications of type 2 diabetes mellitus (T...
OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic ki...
BackgroundThe nonsteroidal mineralocorticoid antagonist finerenone is a new addition to the list of ...
Introduction: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic...
BackgroundGliflozins altering the sodium-glucose transport protein 2 (SGLT2) in the nephron, represe...
BACKGROUND:Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose contransporter-2 i...
Background: It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the...
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with ...
The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) outc...
International audienceAimsFinerenone significantly reduced the risk of kidney and cardiovascular (CV...
Background: The FIDELIO-DKD trial evaluated the effect of the nonsteroidal, selective mineralocortic...
Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patien...
Aim: To evaluate the effect of finerenone by baseline HbA1c, HbA1c variability, diabetes duration an...
Background: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on heart failure (HF) o...
BackgroundThe nonsteroidal mineralocorticoid antagonist finerenone is a new addition to the list of ...
Cardiovascular and renal impairment are the most common complications of type 2 diabetes mellitus (T...
OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic ki...
BackgroundThe nonsteroidal mineralocorticoid antagonist finerenone is a new addition to the list of ...
Introduction: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic...
BackgroundGliflozins altering the sodium-glucose transport protein 2 (SGLT2) in the nephron, represe...
BACKGROUND:Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose contransporter-2 i...
Background: It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the...
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with ...
The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) outc...
International audienceAimsFinerenone significantly reduced the risk of kidney and cardiovascular (CV...
Background: The FIDELIO-DKD trial evaluated the effect of the nonsteroidal, selective mineralocortic...
Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patien...
Aim: To evaluate the effect of finerenone by baseline HbA1c, HbA1c variability, diabetes duration an...
Background: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on heart failure (HF) o...